SCHEMBL20147447

SCHEMBL20147447

CC1CN(C(C)(C)C)CC1Oc1ccccn1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FURIN P09958 1/20 0.41
RET P07949 2/20 0.39
HCRTR2 O43614 3/20 0.35
HCRTR1 O43613 1/20 0.35
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
PDE10A Q9Y233 1/20 0.34
KDM5A P29375 1/20 0.32
NAAA Q02083 1/20 0.32
TSHR P16473 2/20 0.32
KDM4E B2RXH2 1/20 0.31
GPR119 Q8TDV5 1/20 0.31
MC4R P32245 1/20 0.31
MC5R P33032 1/20 0.31
MC1R Q01726 1/20 0.31
KCNH2 Q12809 1/20 0.31
GFER P55789 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20152048 0.81 FURIN (0.42) FURINRETHCRTR2HCRTR1PDE3B
SCHEMBL20069365 0.81 FURIN (0.43) FURINRETHCRTR2HCRTR1PDE3B
SCHEMBL29686345 0.77 GPR119 (0.49) FURINPDE10AGPR119
SCHEMBL28668608 0.75 FURIN (0.42) FURINRETHCRTR2HCRTR1KDM5A
SCHEMBL20205743 0.75 FURIN (0.39) FURINRETHCRTR2HCRTR1PDE3B
SCHEMBL20147464 0.74 PDE3B (0.48) RETHCRTR2HCRTR1PDE3BPDE3A
SCHEMBL21004583 0.74 PDE3B (0.48) RETHCRTR2HCRTR1PDE3BPDE3A
SCHEMBL8130922 0.74 EPHX2 (0.46) RETHCRTR2HCRTR1PDE3BPDE3A
SCHEMBL8253938 0.72 PDE3B (0.44) RETHCRTR2HCRTR1PDE3BPDE3A
SCHEMBL23564044 0.71 GPR119 (0.55) GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-01-05 US disclosed
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-10-15 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 FURIN 2168/4885RET 1/4885HCRTR2 3543/4885
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 FURIN 2168/4885RET 1/4885HCRTR2 3543/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 FURIN 2168/4885RET 1/4885HCRTR2 3543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.